ViiV Healthcare Shares Five-Year Real-World Data for Cabenuva in HIV Treatment

ViiV Healthcare has released five years of real-world evidence from the OPERA cohort, demonstrating the sustained effectiveness and long-term persistence of Cabenuva (cabotegravir and rilpivirine LA) for adults with HIV-1 in the U.S. These findings offer valuable insights into the clinical outcomes of this long-acting HIV treatment.